Ovarian cancer remains the most lethal gynecological malignancy, characterized by high mortality rates and the frequent occurrence of late-stage metastatic diagnoses. While poly(ADP-ribose) polymerase inhibitors (PARPi) have revolutionized ovarian cancer treatment—particularly for patients harboring BRCA1/2 mutations or deficiencies in homologous recombination (HR) repair—the emergence of PARPi resistance and the presence of HR-proficient tumors continue to limit their clinical benefit, underscoring the need for strategies to improve long-term outcomes.
In a recent study published in the Genes & Diseases journal, researchers from the Chinese Academy of Medical Sciences and Peking Union Medical College, Chinese Academy of Sciences, and Mayo Clinic demonstrated that targeting p21-activated kinase 1 (PAK1), a serine/threonine kinase implicated in tumor progression and cellular stress responses, enhances the therapeutic efficacy of PARP inhibition in ovarian cancer.
Using the cBioPortal database, the authors established that elevated PAK1 expression strongly correlates with poor overall survival in ovarian cancer patients. Further investigation demonstrated a positive relationship between PAK1 activity and HR pathways. Since PARP inhibitors exert their strongest anti-cancer effects in cells with defective HR repair, the researchers explored whether disrupting PAK1 could induce HR deficiency and thereby increase sensitivity to PARP-targeted therapies.
Using a combination of genetic and pharmacological approaches, the authors showed that PAK1 deficiency significantly impaired homologous recombination repair without affecting non-homologous end joining. Functional DNA repair assays revealed reduced HR efficiency following PAK1 loss, indicating that PAK1—and importantly, its kinase activity—is required for optimal HR-mediated repair of double-strand DNA breaks. Additionally, reduced RAD51 foci formation, a key marker of homologous recombination activity, further confirmed HR impairment.
When combined with the PARP inhibitor olaparib, PAK1 inhibition produced a pronounced anti-tumor effect. Ovarian cancer cells with reduced PAK1 activity exhibited greater sensitivity to olaparib, accompanied by increased DNA damage accumulation, elevated replication stress, and enhanced activation of cell death pathways, resulting in substantially greater tumor cell killing than either treatment alone.
To evaluate the translational potential of this strategy, the authors employed IPA-3, an allosteric inhibitor of PAK1 kinase activity, and demonstrated that pharmacological blockade of PAK1 reproduced similar effects. DNA fiber assays, chromatin fractionation, and transcriptomic analyses revealed that combining olaparib with IPA-3 increased replication stress, resulting in the accumulation of fatal double-strand breaks, as evidenced by elevated γ-H2AX levels and activation of apoptotic pathways.
To validate these in vitro observations, the researchers employed cell line-derived xenografts, patient-derived organoids, and patient-derived xenograft models. Across all models, combination therapy with olaparib and IPA-3 synergistically suppressed ovarian tumor growth, reduced cellular proliferation, and enhanced apoptosis without exacerbating hepatotoxicity.
In conclusion, this study identifies PAK1 as a critical regulator of homologous recombination repair and a key determinant of PARP inhibitor sensitivity in ovarian cancer. By impairing DNA repair, PAK1 inhibition enhances the anti-tumor activity of PARP inhibitors, leading to increased DNA damage and tumor cell death. These findings highlight the potential of combining PAK1 and PARP inhibitors as a promising therapeutic strategy to overcome resistance and improve treatment outcomes in ovarian cancer.
Reference
Title of the original paper: PAK1 inhibition synergistically enhances the anti-tumor efficacy of PARP inhibitors in ovarian cancers
Journal: Genes & Diseases
Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.
DOI: https://doi.org/10.1016/j.gendis.2025.101887
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus CiteScore: 10.4 | Impact Factor: 14.6
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect ( https://www.sciencedirect.com/journal/genes-and-diseases ).
Submissions to Genes & Diseases may be made using Editorial Manager ( https://www.editorialmanager.com/gendis/default.aspx ).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases ( https://x.com/GenesNDiseases )
Genes & Diseases